Kimryn Rathmell: New drug type in the kidney cancer space and the value of rare disease research

Kimryn Rathmell, Director of National Cancer Institute, shared on X/Twitter:

“I’m excited to see that the discovery of a drug to target HIF-2alpha, first developed for a rare disease (VHL syndrome), is now making a difference in common kidney cancers. This adds a new drug type in the kidney cancer space and highlights the value of rare disease research.”

Source: Kimryn Rathmell/X